[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. 2018;68:7-30.
[2] Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Buscheck F, et al. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European urology. 2018;74:376-86.
[3] von Bodman C, Godoy G, Chade DC, Cronin A, Tafe LJ, Fine SW, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. The Journal of urology. 2010;184:143-8.
[4] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology. 2017;71:618-29.
[5] Muteganya R, Goldman S, Aoun F, Roumeguere T, Albisinni S. Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review. Frontiers in surgery. 2018;5:74.
[6] Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. European urology. 2012;61:480-7.
[7] Memorial Sloan Kettering Cancer Center. Dynamic prostate cancer nomogram: coefficients.
[8] Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, Pavlovich CP, et al. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU international. 2017;119:676-83.
[9] Hueting TA, Cornel EB, Somford DM, Jansen H, van Basten JA, Pleijhuis RG, et al. External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. European urology oncology. 2018;1:411-7.
[10] Grivas N, Wit E, Tillier C, van Muilekom E, Pos F, Winter A, et al. Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection. European journal of nuclear medicine and molecular imaging. 2017;44:2213-26.
[11] Nason GJ, O'Connor EM, MacMahon D, Moss B, Considine SW, Cahill A, et al. Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer. Irish journal of medical science. 2018;187:33-7.
[12] Cimino S, Reale G, Castelli T, Favilla V, Giardina R, Russo GI, et al. Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. Scandinavian journal of urology. 2017;51:345-50.
[13] Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. Journal of magnetic resonance imaging : JMRI. 2012;35:20-31.
[14] Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis. AJR American journal of roentgenology. 2018;210:W95-w109.
[15] Porpiglia F, Manfredi M, Mele F, Bertolo R. Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5. 2018;21:85-91.
[16] Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR American journal of roentgenology. 2006;186:743-8.
[17] Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, et al. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. The Journal of urology. 2018;200:1041-7.
[18] Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, et al. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. European urology. 2019;75:310-8.
[19] Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, et al. The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy. European urology. 2017;71:701-4.
[20] Hou Y, Bao ML, Wu CJ, Zhang J, Zhang YD. A machine learning-assisted decision-support model to better identify patients with prostate cancer requiring an extended pelvic lymph node dissection. 2019;124:972-83.
[21] Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology. 2007;177:540-5.
[22] Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. European urology. 2015;67:1160-7.
[23] Klein S, Staring M Fau - Murphy K, Murphy K Fau - Viergever MA, Viergever Ma Fau - Pluim JPW, Pluim JP. elastix: a toolbox for intensity-based medical image registration.
[24] Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. European urology. 2016;69:16-40.
[25] Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European urology. 2019;76:340-51.
[26] Zhang YD, Wu CJ, Bao ML, Li H, Wang XN, Liu XS, et al. MR-based prognostic nomogram for prostate cancer after radical prostatectomy. Journal of magnetic resonance imaging : JMRI. 2017;45:586-96.
[27] van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Research. 2017;77:e104.
[28] Wallis TSA, Funke CM, Ecker AS, Gatys LA, Wichmann FA, Bethge M. A parametric texture model based on deep convolutional features closely matches texture appearance for humans. J Vis. 2017;17:5.
[29] National Comprehensive Cancer Network. NCCN guidelines https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[30] Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34:2157-64.
[31] Wang T, Gao T, Yang J, Yan X, Wang Y, Zhou X, et al. Preoperative prediction of pelvic lymph nodes metastasis in early-stage cervical cancer using radiomics nomogram developed based on T2-weighted MRI and diffusion-weighted imaging. European journal of radiology. 2019;114:128-35.
[32] Brembilla G, Dell'Oglio P, Stabile A, Ambrosi A, Cristel G, Brunetti L, et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. European radiology. 2018;28:1969-76.
[33] He T, Puppala M, Ezeana CF, Huang YS, Chou PH, Yu X, et al. A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer. JCO clinical cancer informatics. 2019;3:1-12.
[34] Zheng X, Yao Z, Huang Y, Yu Y, Wang Y, Liu Y, et al. Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer. Nature communications. 2020;11:1236.
[35] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology. 2017;71:618-29.
[36] Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. European urology. 2019;75:506-14.
[37] Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, et al. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European urology. 2020.
[38] Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell'Oglio P, Bravi CA, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. European urology. 2017;72:632-40.